Taking evantumumab for several courses will be effective

Amivantamab (amivantamab-vmjw) is a bispecific antibody targeting epidermal growth factor receptor (EGFR) exon 20 insertion mutations and MET gene exon 14 skipping mutations. It is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). However, the efficacy and number of courses of evantumumab will vary due to each patient's specific circumstances and tumor characteristics.

Typically, the efficacy of evantumumab takes several courses of treatment to develop. Specifically, according to data from some clinical studies, patients treated with evantumumab usually need several courses of treatment before seeing significant effects. These effects may include tumor shrinkage, symptom relief, and prolonged survival.

However, it is important to note that the speed of response and degree of efficacy may vary from patient to patient. Some patients may see significant results after just a few courses of treatment, while others may take longer to see results. In addition, some patients may be insensitive to evantuzumab treatment and require alternative treatment options.

Therefore, doctors need to evaluate and adjust the efficacy and number of courses of evantumumab based on the patient's specific conditions. During the treatment process, doctors will closely monitor the patient's condition changes, drug side effects and therapeutic responses, and adjust the treatment plan and number of courses as needed. At the same time, you also need to pay attention to maintaining a good mentality and living habits, actively cooperate with treatment, and improve treatment effects and quality of life.